

GENERAL ANNOUNCEMENT::VOLUNTARY CONTINUATION OF QUARTERLY REPORTING AND DEFERMENT OF HALF-YEARLY REPORTING

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

27-Apr-2020 18:47:46

Status

New

Announcement Sub Title

VOLUNTARY CONTINUATION OF QUARTERLY REPORTING AND DEFERMENT OF HALF-YEARLY REPORTING

Announcement Reference

SG200427OTHRTNEU

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

Attachments

[Hyphens%20-%20Annt Quarterly%20reporting_270420.pdf](#)

Total size = 137K MB

1) **VOLUNTARY CONTINUATION OF QUARTERLY REPORTING FOR FINANCIAL YEAR 2020**
2) **DEFERMENT OF HALF-YEARLY REPORTING TO FINANCIAL YEAR 2021**

INTRODUCTION

On 9 January 2020, the Singapore Exchange Regulation (“**SGX RegCo**”) announced the amendments to Rule 705 of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist (“**Revised Catalist Rules**”) to take effect on 7 February 2020, whereby listed issuers may not be required to release its unaudited financial statements on a quarterly basis (“**Quarterly Reporting**”). Please refer to the announcement dated 9 January 2020 available on the website of SGX for more information.

Hyphens Pharma International Limited (the “**Company**” or “**Hyphens**”, and together with its subsidiaries, the “**Group**”) had on 26 February 2020, announced that the Group will be adopting semi-annual reporting and the next results release will be for the half-year ending 30 June 2020.

1. VOLUNTARY CONTINUATION OF QUARTERLY REPORTING FOR FINANCIAL YEAR 2020

The Board of Directors (“**Board**”) of Hyphens wishes to update shareholders that the Company would voluntarily continue with quarterly reporting for the financial year ending 31 December 2020 and target to release its first quarter unaudited financial results announcement for the period ended 31 March 2020 on 11 May 2020.

The Board recognises that the current COVID-19 pandemic has resulted in business and economic uncertainty and market volatility, and it is important for shareholders and investors to have up-to-date information on the Group’s business and operations during this period. Accordingly, the voluntary continuation of Quarterly Reporting will provide a more timely disclosure of the Group’s business and financial performance to shareholders and investors.

2. DEFERMENT OF HALF-YEARLY REPORTING TO FINANCIAL YEAR 2021

Consequentially, the Board wishes to inform shareholders that the Company and the Group will defer the adoption of releasing the unaudited financial statements on a half-yearly basis to the financial year ending 31 December 2021.

BY ORDER OF THE BOARD

Lim See Wah
Executive Chairman and Chief Executive Officer
Date: 27 April 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. (“**Sponsor**”) for compliance with the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.